Two of Europe’s gene therapy pioneers have reported significant progress in the last week, bringing commercial gene therapy products yet closer to reality.
The UK is setting up a national network to carry out clinical trials of paediatric medicines, filling the gap left by pharmaceutical companies which usually test drugs only on adults.
Nanotechnology is beginning to leave the laboratory and hit the high street – but health scares could stop this commercialisation process in its tracks.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.